1. Kyverna Therapeutics faces a class action securities lawsuit for alleged fraud. 2. The lawsuit claims inaccurate IPO-related statements harmed investors. 3. Investors have until February 7, 2025, to join the lawsuit. 4. Levi & Korsinsky aims to recover losses for affected investors. 5. This marks a significant legal challenge for Kyverna post-IPO.
Class action lawsuits can negatively impact investor confidence and stock prices. Past cases show significant stock drops following similar legal actions.
The lawsuit directly implicates Kyverna's stock performance and integrity, crucial for investors.
Immediate investor sentiment may wane due to ongoing legal proceedings. Historical lawsuits often result in quick declines before stabilization.
Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.
The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's offering documents issued in connection with its February 2024 initial public offering. Follow the link below to get more information and be contacted by a member of our team:
Submit Your Information HereKYTX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
The filed complaint alleges that defendants made false statements and/or concealed that: (i) the strategy to best accomplish the IPO; (ii) the terms of the IPO, including the price at which Kyverna's common stock would be sold; (iii) the language to be used in the Offering Documents; (iv) what disclosures about Kyverna would be made in the Offering Documents; and (v) what responses would be made to the SEC in connection with its review of the Offering Documents. As a result of those constant contacts and communications between the underwriter defendants' representatives and Kyverna's management, directors, and lawyers, at a minimum, the underwriter defendants should have known of Kyverna's undisclosed then-existing problems and plans, and the Offering Document's materially inaccurate, misleading, and incomplete statements and omissions, as detailed herein.
If you suffered a loss in Kyverna Therapeutics, Inc. during the relevant time frame, you have until February 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE Levi & Korsinsky, LLP